Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2460-2468

  Puri, Vibha ^a   Dantuluri, Ajay K ^a   Bansal, Arvind K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Amorphous; Celecoxib; Dissolution; Physical characterization; Solid dispersion; Solid liquid interactions; Solid state; Solid state transformation during dissolution

Indexed keywords

CELECOXIB; MEGLUMINE; POVIDONE;

ARTICLE; CHROMATOGRAPHY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG CAPSULE; DRUG RELEASE; ENCAPSULATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; MOLECULAR INTERACTION; POWDER; SCANNING ELECTRON MICROSCOPY; SOLID; WETTABILITY; X RAY POWDER DIFFRACTION;

EID: 79954592839     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22462     Document Type: Article

References (36)

1. Hilden LR, Morris KR. 2004. Physics of amorphous solids. J Pharm Sci 93:3-12.
2. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
3. Ivanisevic I. 2010. Physical stability studies of miscible amorphous solid dispersions. J Pharm Sci 99:4005-4012.
4. Kaushal AM, Gupta P, Bansal AK. 2004. Amorphous drug delivery systems: Molecular aspects, design and performance. Crit Rev Ther Drug Carrier Syst 21:133-193.
5. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Delivery Rev 48:27-42.
6. Serajuddin ATM. 1999. Solid dispersions of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
7. Sethia S, Squillante E. 2003. Solid dispersions: Revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst 20:217-249.
8. Alonzo DE, Zhang GGZ, Zhou D, Gao Y, Taylor LS. 2010. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res 27:608-618.
9. Chan KLA, Kazarian SG. FTIR spectroscopic imaging of dissolution of a solid dispersion of nifedipine in poly(ethylene glycol). Mol Pharm 1:331-335.
10. Drooge DJV, Hinrichs WLJ, Frijlink HW. 2004. Anomalous dissolution behavior of tablets prepared from sugar glass-based solid dispersions. J Control Release 97:441-452.
11. Savolainena M, Kogermanna K, Heinzc A, Aaltonena J, Peltonena L, Strachand CJ, Yliruusi J. 2009. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Sci 71:71-79.
12. Corrigan OI. 1985. Mechanisms of dissolution of fast release solid dispersions. Drug Dev Ind Pharm 11:697-724.
13. Craig DQM. 2002. The mechanisms of drug release from solid dispersions in water-soluble matrix. Int J Pharm 231:131-144.
14. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
15. Tobyn M, Brown J, Dennis AB, Fakes M, Gao Q, Gamble J, Khimyak YZ, Mcgeorge G, Patel C, Sinclair W, Timmins P, Yin S. 2009. Amorphous drug-PVP dispersions: Application of theoretical, thermal and spectroscopic analytical techniques to the study of a molecule with intermolecular bonds in both the crystalline and pure amorphous state. J Pharm Sci 98:3456-3468.
16. Akbuga J, Gursoy A, Yetimoglu F. 1988. Preparation and properties of tablets prepared from furosemide-PVP solid dispersion systems. Drug Dev Ind Pharm 14:2091-2108.
17. Ford JL, Rubinstein MH. 1980. Formulation and aging of tablets prepared from indomethacin-poly(ethylene glycol) 6000 solid dispersions. Pharm Acta Helv 55:1-7.
18. Goddeeris C, Willems T, Mooter GV. 2008. Formulation of fast disintegrating tablets of ternary solid dispersions of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781. Eur J Pharm Sci 34:293-302.
19. Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. 1988. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci 77:414-417.
20. Gupta P, Bansal AK. 2005. Molecular interactions in celecoxib-PVP-meglumine amorphous system. J Pharm Pharmacol 57:303-310.
21. Gupta P, Bansal AK. 2005. Spray drying for generation of a ternary amorphous system of celecoxib, PVP and meglumine. Pharm Dev Tech 10:273-281.
22. Gupta P, Bansal AK. 2005. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility. Pharmazie 60:830-836.
23. Gupta P, Bansal AK. 2006. Oral bioavailability advantage from stabilized amorphous systems of celecoxib. J Pharm Res 5:15-24.
24. Puri V, Dantuluri AK, Kumar M, Karar N, Bansal AK. 2010. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci 40:84-93.
25. Khan KA. 1975. The concept of dissolution efficiency. J Pharm Pharmacol 27:48-49.
26. Bansal AK, Mulla M, Kakumanu VK. 2006. Criticality of functional excipients and decoding methods during generic product development. Pharm Technol Eur 18:34-38.
27. Mulla M. 2005. Reverse engineering of pharmaceutical formulations. M. Pharm. Thesis. Punjab, India: Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research.
28. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. 2005. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharm 2:384-391.
29. Ahlqvist MU, Taylor LS. 2002. Water diffusion in hydrated crystalline and amorphous sugars monitored using H/D exchange. J Pharm Sci 91:690-698.
30. Rafferty DW, Koenig JL. 2002. FTIR imaging for the characterization of controlled-release drug delivery applications. J Control Release 83:29-39.
31. Paulson S, Vaughn M, Jessen S, Lawal Y, Gresk CJ, Yan B, Maziasz T, Cook C, Karim A. 2001. Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. J Pharmacol Exp Ther 297:638-645.
32. Gupta P, Chawla G, Bansal AK. 2004. Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Mol Pharm 1:406-413.
33. Gupta P, Kakumanu VK, Bansal AK. 2004. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res 21:1762-1769.
34. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. 2003. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci 20:305-317.
35. Rumondor ACF, Marsac PJ, Stanford LA, Taylor LS. 2009. Phase behavior of poly(vinylpyroliddone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 6:1492-1505.
36. Ping ZH, Nguyen QT, Chen SM, Zhou JQ, Ding YD. 2001. States of water in different hydrophilic polymers-DSC and FTIR studies. Polymers 42:8461-8467.